InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

Download PDF Copy

Jun 18 2010

InteKrin Therapeutics Inc. announced today it will present 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® pioglitazone, at the American Diabetes Association annual meeting in Orlando, FL, Monday, June 28, 2010 at 2:45 pm EDT during the "Update on BARI 2D --Treatment of Insulin Resistance" session.

Dr. Alex DePaoli, Acting Chief Medical Officer of InteKrin Therapeutics, will present "INT131 Besylate, a Selective PPAR-gamma Modulator (SPPARM), Improved Glycemic Control in Patients with Type 2 Diabetes without Causing the Edema Seen with Pioglitazone."

SOURCE InteKrin Therapeutics Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: Diabetes, Edema, Endocrinology, Insulin, Insulin Resistance, Metabolism, Obesity, Pioglitazone, Therapeutics, Type 1 Diabetes, Type 2 Diabetes, Type I Diabetes

Comments (0)

Download PDF Copy

Suggested Reading

A novel approach to prevent severe liver disease in diabetes

A novel approach to prevent severe liver disease in diabetes

Metabolomic biomarkers improve diabetes risk prediction accuracy

Metabolomic biomarkers improve diabetes risk prediction accuracy

Study reveals gaps in gestational diabetes diagnosis in pregnant women

Study reveals gaps in gestational diabetes diagnosis in pregnant women

Can HIIT's metabolic benefits last? New study explores post-exercise sustainability in diabetes

Can HIIT's metabolic benefits last? New study explores post-exercise sustainability in diabetes

Five servings of dark chocolate a week may protect against type 2 diabetes

Five servings of dark chocolate a week may protect against type 2 diabetes

Replacing carbohydrates with protein and fat improves cholesterol profiles in type 2 diabetes

Replacing carbohydrates with protein and fat improves cholesterol profiles in type 2 diabetes

Can fasting improve diabetes outcomes? Ramadan offers insights

Can fasting improve diabetes outcomes? Ramadan offers insights

Danish studies find increased risk of optic nerve damage with diabetes medicine

Danish studies find increased risk of optic nerve damage with diabetes medicine

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Eating breakfast later lowers blood sugar spikes in type 2 diabetes patients